83-5965-85　IFNG, Emapalumab Biosimilar 5mg　591823

特徴

• Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma.
• Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.1,5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.5 As well, emapalumab was given the status of PRIME by the EMA.
• Applications:Suitable for use in Functional Assays.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

仕様

• Size：5mg
• 抗体種類：Mab
• 宿主：human
• Source Antibody：human
• Grade：Affinity Purified
• Purity：Purified by Protein A/G affinity chromatography. ≥95%. Endotoxin: ≤1EU/mg (LAL)
• Form：Supplied as a liquid in PBS, pH 7.4. No preservative added.
• Specificity：Recognizes human IFN-gamma. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Emapalumab
• Isotype：IgG1(K214R),k
• Calc Crossreactivity：Hu
• Immunogen：Recombinant protein corresponding to humanized IFNG, expressed in CHO cells.
• この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
• 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]